Do I need a prescription for Taurine 500mg capsules?

Taurine 500mg capsules is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Taurine 500mg capsules?

Taurine 500mg capsules is the generic name. It is available under brand names including: AceTaur 500mg capsules, EN-Taurine 500mg capsules, Lamberts Taurine 500mg capsules, O-Due 500mg capsules, Solgar Taurine 500mg capsules and 2 more. (Source: NHS dm+d — Actual Medicinal Products)

Taurine 500mg capsules

Prescription only

Requires a prescription from a doctor or prescriber

Capsule

500mg

Oral

Taurine, whose chemical name is 2-aminoethanesulfonic acid, is one of the most abundant amino acids in several organs.

Active ingredients:

Taurine

BNF classificationBrowse formulary

Where this medicine sits in the British National Formulary — the UK's standard prescribing reference

BNF 09.11.01

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Check interactions for Taurine

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Official medicine documents

Yellow Card

Report side effects (MHRA)

Drug safety updates

MHRA alerts for Taurine

Source: MHRA Products DatabaseOGL 3.0

Updated 3 months ago(16 Jan 2026)

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Taurine

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

Search EudraVigilance database

Browse substances A–Z in the European adverse reaction database

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

7 branded products available

7 productsShow details

7 products

Possibly available on the UK marketRestricted supplyDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Taurine on the MHRA register

AceTaur 500mg capsules

Essential-Healthcare Ltd

None

EN-Taurine 500mg capsules

Ennogen Healthcare International Ltd

None

Lamberts Taurine 500mg capsules

Lamberts Healthcare Ltd

None

Solgar Taurine 500mg capsules

Solgar Vitamin and Herb

None

TauriDose 500mg capsules

TriOn Pharma Ltd

None

Taurine 500mg capsules

Special Order

None

Special

O-Due 500mg capsules

Teofarma S.r.l.

None

Discontinued

Source: NHS dm+dOGL 3.0

Updated about 1 month ago(1 Mar 2026)

Therapeutically similar medicines

10 similarShow details

Generic Vivomixx drops

Other

Same BNF section

Generic HealthAid Colonease Plus capsules

Capsule

Same BNF section

Arginine 500mg/5ml oral solution sugar free

Oral solution

500mg/5ml

Same BNF section

Ubidecarenone 25mg/5ml oral solution sugar free

Oral solution

25mg/5ml

Same BNF section

Ubidecarenone 50mg/5ml oral solution sugar free

Oral solution

50mg/5ml

Same BNF section

Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Show details

Loading prescribing data...

Clinical guidelines and formulary information

British National Formulary

Taurine

BNF

Drug monograph — bnf.nice.org.uk

Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Show details

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & product information

Official product databases and supply status monitoring

Shortages info

NHS Specialist Pharmacy Service (SPS)

emc product search

Discontinuations & alternatives for Taurine

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.

Codes for healthcare professionals and prescribing systems

Show details

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

7400611000001100

dm+d ID

7400611000001100

VTM (Virtual Therapeutic Moiety)

777680001

VMP (Virtual Medicinal Product)

7400611000001100

BNF code

09110100

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA).

Active and completed clinical studies from ClinicalTrials.gov

Show details

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

None known

Half-life

0.7-1.4 h

Mechanism

The diet supplements containing taurine function by replacing the missing nutriments in the body.

Food interactions

None known

Human targets

7 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

1-30 mg/k

Oral administration of taurine was studied and it reported dose-dependent values of AUC, Cmax and tmax wherein a dose of 1-30 mg/kg ranged from 89-3452 mcg min/L, 2-15.7…

Half-life

0.7-1.4 h

Oral administration of taurine in healthy individuals gave a plasma elimination half-life that ranged from 0.7-1.4 h.
[A31400]

Protein binding

Taurine is highly bound to plasma proteins and retained in the plasma fraction.
[A31405]

Volume of distribution

299-353 ml

The distribution of taurine was studied under the two-compartment model and each one of the compartments gave a range for the volume of distribution…

Metabolism

Taurine can be metabolized by diverse organisms to form different types of metabolites derived from the original form of taurine.…

Elimination

Taurine flows and gets distributed in veins and arteries and reports have observed the presence of a significant released of taurine in portally…

Clearance

1 mg/k

The clearance rate of orally administered taurine was reported to be dose-dependent wherein a dose of 1 mg/kg it presents a clearance rate of 11.7…

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Investigational

Nutraceutical

Small molecule

About this compound

Taurine, whose chemical name is 2-aminoethanesulfonic acid, is one of the most abundant amino acids in several organs. It plays important role in essential biological processes.[A31396] This conditional amino acid can be either be manufactured by the body or obtained in the diet mainly by the consumption of fish and meat.[L1058] The supplements containing taurine were FDA approved by 1984 and they are hypertonic injections composed by cristalline amino acids.[FDA label]

Properties:

solid

Avg. mass: 125.15 Da

View FDA drug label

DrugBank indication

The use of diet supplements containing taurine is indicated for the nutritional support of infants and young pediatric patients requiring total parenteral nutrition via central or peripheral routes. The usage of diet supplements containing taurine prevents nitrogen and weight loss or to treat negative nitrogen balance in pediatric patients where the alimentary tract cannot be done through oral, gastrostomy or jejunostomy administration, there is impaired gastrointestinal absorption or protein requirements are substantially increased.[FDA label]

Also known as(93)

Aminoethylsulfonic acid

Taurine

Taurineold

GluN2B

Glutamate [NMDA] receptor subunit epsilon-2

hNR3

N-methyl D-aspartate receptor subtype 2B

N-methyl-D-aspartate receptor subunit 3

Dosage forms(26)

Solution (Parenteral)

Injection, solution (Intravenous)

Injection (Intravenous) — 11.000 g/1000ml

Solution (Intravenous) — 18.5 g/L

Injection (Intravenous) — 5.5 g/1000ml

Syrup (Oral)

Tablet, chewable (Oral)

Liquid (Oral)

Molecular properties(19)

Toxicity & overdose

The administration of taurine has been correlatefd to significant in the hypothalamus and the modification of neuroendocrine functions. Other than that, taurine administration in regular doses is reported by different articles and institutions to be safe.
[A31406]

How it works

Mechanism of action

The diet supplements containing taurine function by replacing the missing nutriments in the body. Taurine, as a single agent, presents different functions like substrate for formation of bile salts, cell volume regulation, modulation of intracellular calcium, cytoprotection of central nervous system, etc.[A31398]

Pharmacodynamics

The diet supplements containing taurine are formulated as a well-tolerated nitrogen source for nutritional support. Administration of diet supplements regulates the level of plasma amino acid concentration, nitrogen balance, weight and serum protein concentration to reach normal values, thus improving the nutritional status.[FDA label]

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

Oral administration of taurine was studied and it reported dose-dependent values of AUC, Cmax and tmax wherein a dose of 1-30 mg/kg ranged from 89-3452 mcg min/L, 2-15.7 mcg min/ml and 15 min respectively.
[A31399]
Further studies in healthy individuals gave an AUC, Cmax and tmax in the range of 116-284.5 mg h/L, 59-112.6 mg/L and 1-2.5 h.
[A31400]

Half-life

Oral administration of taurine in healthy individuals gave a plasma elimination half-life that ranged from 0.7-1.4 h.
[A31400]

Protein binding

Taurine is highly bound to plasma proteins and retained in the plasma fraction.
[A31405]

Volume of distribution

The distribution of taurine was studied under the two-compartment model and each one of the compartments gave a range for the volume of distribution of 299-353 ml/kg in compartment 1 and 4608-8374 ml/kg in compartment 2 in mice.
[A31399]
Further studies in healthy indivudals gave a volume of distribution that ranged from 19.8 to 40.7 L.
[A31400]

Metabolism

Taurine can be metabolized by diverse organisms to form different types of metabolites derived from the original form of taurine. In the human, the pathways that form the metabolism of taurine are divided in the formation of 5-glutamyl-taurine by the action of the enzyme gamma-glutamyltransferase 6 or the formation of taurocholate by the action of the bile acid-CoA:amino acid N-acyltransferase.
[L1060]

Route of elimination

Taurine flows and gets distributed in veins and arteries and reports have observed the presence of a significant released of taurine in portally drained viscera, thus suggesting that the main elimination route of taurine is by the gut. This elimination route may be explained by the enterohepatic cycle of taurine.
[A31404]

Clearance

The clearance rate of orally administered taurine was reported to be dose-dependent wherein a dose of 1 mg/kg it presents a clearance rate of 11.7 ml min/kg, 10 mg/kg generates a clearance rate of 18.7 ml min/kg and a dose of 30 mg/kg reports a clearance rate of 9.4 ml min/kg.
[A31399]
Further studies in healthy individuals generate a clearance rate that ranged from 14 to 34.4 L/h.
[A31400]

Drug targets(7)

Proteins and enzymes this drug interacts with in the body

Glutamate receptor ionotropic, NMDA 2B

BE0000417

GRIN2B

inhibitor

Specific functionamyloid-beta binding

Cellular location

Cell membrane

General function & pharmacology

Component of N-methyl-D-aspartate (NMDA) receptors (NMDARs) that function as heterotetrameric, ligand-gated cation channels with high calcium permeability and voltage-dependent block by Mg(2+) .
PMID:24272827 PMID:24863970 PMID:26875626 PMID:26919761 PMID:27839871 PMID:28095420 PMID:28126851 PMID:38538865 PMID:8768735

Participates in synaptic plasticity for learning and memory formation by contributing to the long-term depression (LTD) of hippocampus membrane currents (By similarity). Channel activation requires binding of the neurotransmitter L-glutamate to the GluN2 subunit, glycine or D-serine binding to the GluN1 subunit, plus membrane depolarization to eliminate channel inhibition by Mg(2+) .
PMID:24272827 PMID:24863970 PMID:26875626 PMID:26919761 PMID:27839871 PMID:28095420 PMID:28126851 PMID:38538865 PMID:8768735

NMDARs mediate simultaneously the potasium efflux and the influx of calcium and sodium (By similarity). Each GluN2 subunit confers differential attributes to channel properties, including activation, deactivation and desensitization kinetics, pH sensitivity, Ca2(+) permeability, and binding to allosteric modulators .
PMID:26875626 PMID:28095420 PMID:28126851 PMID:38538865 PMID:8768735

In concert with DAPK1 at extrasynaptic sites, acts as a central mediator for stroke damage.

Its phosphorylation at Ser-1303 by DAPK1 enhances synaptic NMDA receptor channel activity inducing injurious Ca2+ influx through them, resulting in an irreversible neuronal death (By similarity)

Gamma-aminobutyric acid receptor subunit theta

BE0004797

GABRQ

agonist

Specific functionGABA-A receptor activity

Cellular location

Postsynaptic cell membrane

General function & pharmacology

Theta subunit of the heteropentameric ligand-gated chloride channel gated by gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the brain .
PMID:10449790 PMID:16412217
GABA-gated chloride channels, also named GABA(A) receptors (GABAAR), consist of five subunits arranged around a central pore and contain GABA active binding site(s) located at the alpha and beta subunit interfaces (By similarity). When activated by GABA, GABAARs selectively allow the flow of chloride anions across the cell membrane down their electrochemical gradient PMID:10449790 PMID:16412217

Gamma-aminobutyric acid type B receptor subunit 1

BE0000217

GABBR1

agonist

Specific functionextracellular matrix protein binding

Cellular location

Cell membrane

General function & pharmacology

Component of a heterodimeric G-protein coupled receptor for GABA, formed by GABBR1 and GABBR2 .
PMID:15617512 PMID:18165688 PMID:22660477 PMID:24305054 PMID:36103875 PMID:9872316 PMID:9872744

Within the heterodimeric GABA receptor, only GABBR1 seems to bind agonists, while GABBR2 mediates coupling to G proteins .
PMID:18165688
Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase .
PMID:10075644 PMID:10773016 PMID:10906333 PMID:24305054 PMID:9872744

Signaling inhibits adenylate cyclase, stimulates phospholipase A2, activates potassium channels, inactivates voltage-dependent calcium-channels and modulates inositol phospholipid hydrolysis .
PMID:10075644
Calcium is required for high affinity binding to GABA (By similarity). Plays a critical role in the fine-tuning of inhibitory synaptic transmission .
PMID:9844003
Pre-synaptic GABA receptor inhibits neurotransmitter release by down-regulating high-voltage activated calcium channels, whereas postsynaptic GABA receptor decreases neuronal excitability by activating a prominent inwardly rectifying potassium (Kir) conductance that underlies the late inhibitory postsynaptic potentials .
PMID:10075644 PMID:22660477 PMID:9844003 PMID:9872316 PMID:9872744

Not only implicated in synaptic inhibition but also in hippocampal long-term potentiation, slow wave sleep, muscle relaxation and antinociception (Probable). Activated by (-)-baclofen, cgp27492 and blocked by phaclofen PMID:24305054 PMID:9844003 PMID:9872316

Glycine receptor subunit alpha-1

BE0000433

GLRA1

agonist

Specific functionextracellularly glycine-gated chloride channel activity

Cellular location

Postsynaptic cell membrane

General function & pharmacology

Subunit of heteromeric glycine-gated chloride channels .
PMID:14551753 PMID:23994010 PMID:25730860 PMID:37821459

Plays an important role in the down-regulation of neuronal excitability .
PMID:8298642 PMID:9009272
Contributes to the generation of inhibitory postsynaptic currents .
PMID:25445488
Channel activity is potentiated by ethanol .
PMID:25973519
Potentiation of channel activity by intoxicating levels of ethanol contribute to the sedative effects of ethanol (By similarity)

Glycine receptor subunit beta

BE0000055

GLRB

agonist

Specific functionextracellularly glycine-gated chloride channel activity

Cellular location

Postsynaptic cell membrane

General function & pharmacology

Subunit of heteromeric glycine-gated chloride channels .
PMID:11929858 PMID:15302677 PMID:16144831 PMID:22715885 PMID:23238346 PMID:25445488 PMID:34473954 PMID:8717357

Plays an important role in the down-regulation of neuronal excitability .
PMID:11929858 PMID:23238346
Contributes to the generation of inhibitory postsynaptic currents PMID:25445488

Metabolizing enzymes(2)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

TGM6Protein-glutamine gamma-glutamyltransferase 6

substrate

BAATBile acid-CoA:amino acid N-acyltransferase

substrate

Transporters(3)

Proteins that transport this drug across cell membranes

Proton-coupled amino acid transporter 1

BE0000536

SLC36A1

substrate

Specific functionABC-type taurine transporter transporter activity

Cellular location

Cell membrane

General function & pharmacology

Electrogenic proton/amino acid symporter with selectivity for small apolar L-amino acids, their D-enantiomers and selected amino acid derivatives such as 4-aminobutanoate/GABA .
PMID:12527723 PMID:12809675 PMID:19549785

May be involved in the efflux from the lysosomal compartment of neutral amino acids resulting from proteolysis (By similarity). May play a role in specifying sites for exocytosis in neurons (By similarity)

Sodium- and chloride-dependent taurine transporter

BE0009148

SLC6A6

substrate

Specific functionalanine transmembrane transporter activity

Cellular location

Cell membrane

General function & pharmacology

Mediates sodium- and chloride-dependent transport of taurine .
PMID:31345061 PMID:31903486 PMID:8010975 PMID:8382624 PMID:8654117

Mediates transport of beta-alanine .
PMID:8010975
Can also mediate transport of hypotaurine and gamma-aminobutyric acid (GABA) (By similarity)

Solute carrier family 15 member 1

BE0001018

SLC15A1

substrate

Specific functiondipeptide transmembrane transporter activity

Cellular location

Apical cell membrane

General function & pharmacology

Electrogenic proton-coupled amino-acid transporter that transports oligopeptides of 2 to 4 amino acids with a preference for dipeptides. Transports neutral and monovalently charged peptides with a proton to peptide stoichiometry of 1:1 or 2:1 (By similarity) .
PMID:15521010 PMID:18367661 PMID:19685173 PMID:26320580 PMID:7896779 PMID:8914574 PMID:9835627

Primarily responsible for the absorption of dietary di- and tripeptides from the small intestinal lumen (By similarity). Mediates transepithelial transport of muramyl and N-formylated bacterial dipeptides contributing to recognition of pathogenic bacteria by the mucosal immune system PMID:15521010 PMID:9835627

Biological pathways(8)

Taurine and Hypotaurine Metabolism

metabolic

Involved compounds

Taurine,Cysteamine,Iron,Cysteine,Pyridoxal phosphate

Bile Acid Biosynthesis

metabolic

Involved compounds

Deoxycholic acid,Taurine,ATP,Chenodeoxycholic acid,Cholesterol,Cholic Acid,Pyrophosphoric acid,Flavin adenine dinucleotide,Glycine,Iron,Mesoheme,NADH,Palmitic Acid,Taurochenodeoxycholic acid,Taurocholic acid

Congenital Bile Acid Synthesis Defect Type II

disease

Involved compounds

Cerebrotendinous Xanthomatosis (CTX)

disease

Involved compounds

Zellweger Syndrome

disease

Involved compounds

Familial Hypercholanemia (FHCA)

disease

Involved compounds

Congenital Bile Acid Synthesis Defect Type III

disease

Involved compounds

27-Hydroxylase Deficiency

disease

Involved compounds

Scientific references(7)

Olson J.E., Martinho E Jr

Regulation of taurine transport in rat hippocampal neurons by hypo-osmotic swelling.

Journal Neurochem

2006 Mar96(5):1375-89. doi: 10.1111/j.1471-4159.2006.03652.x

PMID: 16478528 DOI: 10.1111/j.1471-4159.2006.03652.x

Ripps H., Shen W.

Heritability of scoliosis.

Grauers A, Rahman I, Gerdhem P

Eur Spine J 2011 Nov 18. [Epub ahead of print]. The Spine Journal. 201212(1):85. doi: 10.1016/j.spinee.2011.12.013

PMID: 23170060 DOI: 10.1016/j.spinee.2011.12.013

Nielsen C.U., Bjerg M., Ulaganathan N., Holm R.

Oral and intravenous pharmacokinetics of taurine in sprague-dawley rats: the influence of dose and the possible involvement of the proton-coupled amino acid transporter, PAT1, in oral taurine absorption.

Physiology Reports

2017 Oct5(19). pii: 5/19/e13467. doi: 10.14814/phy2.13467. Epub 2017 Oct 16

PMID: 29038364 DOI: 10.14814/phy2.13467

Ghandforoush-Sattari M., Mashayekhi S., Krishna C.V., Thompson J.P., Routledge P.A.

Pharmacokinetics of oral taurine in healthy volunteers.

Journal Amino Acids

20102010:346237. doi: 10.4061/2010/346237. Epub 2010 Jun 29

PMID: 22331997 DOI: 10.4061/2010/346237

van Stijn M.F., Vermeulen M.A., Siroen M.P., Wong L.N., van den Tol M.P., Ligthart-Melis G.C., Houdijk A.P., van Leeuwen P.A.

Human taurine metabolism: fluxes and fractional extraction rates of the gut, liver, and kidneys.

Metabolism

2012 Jul61(7):1036-40. doi: 10.1016/j.metabol.2011.12.005. Epub 2012 Feb 2

PMID: 22304837 DOI: 10.1016/j.metabol.2011.12.005

Tang D.Q., Li Y.J., Li Z., Bian T.T., Chen K., Zheng X.X., Yu Y.Y., Jiang S.S.

Study on the interaction of plasma protein binding rate between edaravone and taurine in human plasma based on HPLC analysis coupled with ultrafiltration technique.

Biomed Chromatogr

2015 Aug29(8):1137-45. doi: 10.1002/bmc.3401. Epub 2014 Dec 26

PMID: 25545282 DOI: 10.1002/bmc.3401

Mantovani J., DeVivo D.C.

Effects of Taurine on Seizures and Growth Hormone Release in Epileptic Patients.

Archives of Neurology

197936(11):672-674. doi: 10.1001/archneur.1979.00500470042006

PMID: 508122 DOI: 10.1001/archneur.1979.00500470042006

Affected organisms(1)

Humans and other mammals

Experimental properties(4)

Protein Data Bank entries(25)

Commercial products(28)

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Taurine

DB01956

CAS number

107-35-7

UNII (FDA)

1EQV5MLY3D

InChI Key (molecular fingerprint)

XOAAWQZATWQOTB-UHFFFAOYSA-N

Additional database identifiers

Drugs Product Database (DPD)

1366

ChEBI

15891

PubChem Compound

1123

PubChem Substance

46506189

KEGG Compound

C00245

KEGG Drug

D00047

ChemSpider

1091

BindingDB

50357220

PharmGKB

PA451590

PDB

TAU

IUPHAR

2379

Guide to Pharmacology

2379

Wikipedia

Taurine

ChEMBL

CHEMBL239243

ZINC

ZINC000003809490

RxCUI

10337

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4586

GenAtlas

GRIN2B

GeneCards

GRIN2B

GenBank Gene Database

U90278

GenBank Protein Database

1899202

IUPHAR

457

Guide to Pharmacology

457

UniProtKB

Q13224

UniProt Accession

NMDE2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4075

GenAtlas

GABRA1

GeneCards

GABRA1

GenBank Gene Database

X13584

GenBank Protein Database

31631

IUPHAR

404

Guide to Pharmacology

404

UniProtKB

P14867

UniProt Accession

GBRA1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4076

GenAtlas

GABRA2

GeneCards

GABRA2

GenBank Gene Database

S62907

GenBank Protein Database

386422

IUPHAR

405

Guide to Pharmacology

405

UniProtKB

P47869

UniProt Accession

GBRA2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4077

GenAtlas

GABRA3

GeneCards

GABRA3

GenBank Gene Database

S62908

GenBank Protein Database

386424

IUPHAR

406

Guide to Pharmacology

406

UniProtKB

P34903

UniProt Accession

GBRA3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4078

GenAtlas

GABRA4

GeneCards

GABRA4

GenBank Gene Database

U30461

GenBank Protein Database

905393

IUPHAR

407

Guide to Pharmacology

407

UniProtKB

P48169

UniProt Accession

GBRA4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4079

GenAtlas

GABRA5

GeneCards

GABRA5

GenBank Gene Database

L08485

GenBank Protein Database

182916

IUPHAR

408

Guide to Pharmacology

408

UniProtKB

P31644

UniProt Accession

GBRA5_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4080

GenAtlas

GABRA6

GeneCards

GABRA6

GenBank Gene Database

S81944

GenBank Protein Database

1470364

IUPHAR

409

Guide to Pharmacology

409

UniProtKB

Q16445

UniProt Accession

GBRA6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4081

GenAtlas

GABRB1

GeneCards

GABRB1

GenBank Gene Database

X14767

GenBank Protein Database

31635

IUPHAR

410

UniProtKB

P18505

UniProt Accession

GBRB1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4082

GenAtlas

GABRB2

GeneCards

GABRB2

GenBank Gene Database

S67368

GenBank Protein Database

455946

IUPHAR

411

UniProtKB

P47870

UniProt Accession

GBRB2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4083

GenAtlas

GABRB3

GeneCards

GABRB3

GenBank Gene Database

M82919

GenBank Protein Database

182925

IUPHAR

412

Guide to Pharmacology

412

UniProtKB

P28472

UniProt Accession

GBRB3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4084

GeneCards

GABRD

GenBank Gene Database

AF016917

GenBank Protein Database

2388693

UniProtKB

O14764

UniProt Accession

GBRD_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4085

GeneCards

GABRE

GenBank Gene Database

U66661

GenBank Protein Database

1857126

UniProtKB

P78334

UniProt Accession

GBRE_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4086

GeneCards

GABRG1

GenBank Gene Database

AK122845

GenBank Protein Database

193783776

UniProtKB

Q8N1C3

UniProt Accession

GBRG1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4087

GeneCards

GABRG2

GenBank Gene Database

X15376

GenBank Protein Database

31637

UniProtKB

P18507

UniProt Accession

GBRG2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4088

GeneCards

GABRG3

GenBank Gene Database

S82769

GenBank Protein Database

1754749

UniProtKB

Q99928

UniProt Accession

GBRG3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4089

GeneCards

GABRP

GenBank Gene Database

U95367

GenBank Protein Database

2197001

UniProtKB

O00591

UniProt Accession

GBRP_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:14454

GeneCards

GABRQ

GenBank Gene Database

AF189259

GenBank Protein Database

7861736

UniProtKB

Q9UN88

UniProt Accession

GBRT_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4070

GenAtlas

GABBR1

GeneCards

GABBR1

GenBank Gene Database

AJ225028

GenBank Protein Database

3892594

IUPHAR

240

Guide to Pharmacology

240

UniProtKB

Q9UBS5

UniProt Accession

GABR1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4326

GenAtlas

GLRA1

GeneCards

GLRA1

GenBank Gene Database

X52009

GenBank Protein Database

31851

IUPHAR

423

Guide to Pharmacology

423

UniProtKB

P23415

UniProt Accession

GLRA1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4329

GenAtlas

GLRB

GeneCards

GLRB

GenBank Gene Database

U33267

GenBank Protein Database

992687

IUPHAR

427

Guide to Pharmacology

427

UniProtKB

P48167

UniProt Accession

GLRB_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4328

GenAtlas

GLRA3

GeneCards

GLRA3

GenBank Gene Database

AF017724

GenBank Protein Database

3342792

IUPHAR

425

Guide to Pharmacology

425

UniProtKB

O75311

UniProt Accession

GLRA3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4327

GenAtlas

GLRA2

GeneCards

GLRA2

GenBank Gene Database

X52008

GenBank Protein Database

31849

IUPHAR

424

Guide to Pharmacology

424

UniProtKB

P23416

UniProt Accession

GLRA2_HUMAN

GenBank Gene Database

D85613

GenBank Protein Database

1384060

UniProtKB

P37610

UniProt Accession

TAUD_ECOLI

GenBank Gene Database

U20191

GenBank Protein Database

882252

UniProtKB

P54965

UniProt Accession

CBH_CLOPE

HUGO Gene Nomenclature Committee (HGNC)

HGNC:16255

GenAtlas

TGM6

GeneCards

TGM6

GenBank Gene Database

AF540969

UniProtKB

O95932

UniProt Accession

TGM3L_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:932

GenAtlas

BAAT

GeneCards

BAAT

GenBank Gene Database

L34081

GenBank Protein Database

532505

UniProtKB

Q14032

UniProt Accession

BAAT_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:18761

GenAtlas

SLC36A1

GeneCards

SLC36A1

GenBank Gene Database

AF516142

GenBank Protein Database

31324239

Guide to Pharmacology

1161

UniProtKB

Q7Z2H8

UniProt Accession

S36A1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:11052

GeneCards

SLC6A6

UniProtKB

P31641

UniProt Accession

SC6A6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10920

GenAtlas

SLC15A1

GeneCards

SLC15A1

GenBank Gene Database

U13173

GenBank Protein Database

773588

Guide to Pharmacology

984

UniProtKB

P46059

UniProt Accession

S15A1_HUMAN

DrugBank citations

If you use DrugBank data in your research, please cite the following publications:

Knox C., Wilson M., Klinger C.M., et al

DrugBank 6.

0: the DrugBank Knowledgebase for 2024

Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275

PMID: 37953279

Wishart D.S., Feunang Y.D., Guo A.C., et al

DrugBank 5.

0: a major update to the DrugBank database for 2018

Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082

PMID: 29126136

Show earlier publications

Law V., Knox C., Djoumbou Y., et al

DrugBank 4.

0: shedding new light on drug metabolism

Nucleic Acids Res. 2014 Jan 142(1):D1091-7

PMID: 24203711

Knox C., Law V., Jewison T., et al

DrugBank 3.

0: a comprehensive resource for 'omics' research on drugs

Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41

PMID: 21059682

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Nucleic Acids Research

2008 Jan36(Database issue):D901-6

PMID: 18048412

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Nucleic Acids Research

2006 Jan 134(Database issue):D668-72

PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated 26 days ago(8 Mar 2026)

Back to medicines

Taurine 500mg capsules

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

British National Formulary

Pharmacy stock checkers

Supply & product information

NHS UK identifiers

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clearance

Clinical essentials

Pharmacology

Deep science
20

Chemical identifiers

Taurine

Additional database identifiers

DrugBank citations

Taurine 500mg capsules

Safety & regulatory

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

Medicines like this

Prescribing statistics

Guidance (NICE / BNF)

British National Formulary

Availability, stocks & shortages

Pharmacy stock checkers

Supply & product information

Professional identifiers

NHS UK identifiers

Clinical trials

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clearance

Clinical essentials

Pharmacology

Deep science20

Chemical identifiers

Taurine

Additional database identifiers

DrugBank citations

Deep science
20